Three-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study
Open Access
- 3 February 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Abstract
The long-term impact of left atrial appendage occlusion (LAAO) plus ablation for atrial fibrillation remains controversial. The present study aims to compare the three-year clinical outcomes of LAAO patients with or without one-staged ablation. The RECORD study (NCT03917563) was a prospective registry conducted in 39 participating sites in China between 1 April 2019 and 31 October 2020, which consecutively enrolled 3082 patients who successfully received the WATCHMAN LAAO device. The current study compared patients who received LAAO only to patients who underwent LAAO plus ablation. A 1:1 propensity score matching was performed to attenuate confounding. The primary outcome was a composite endpoint of cardiovascular death, stroke, and systemic embolism at 3-year. 1633/2928 (55.8%) patients received LAAO only and 1295/2928 (44.2%) received LAAO plus ablation. After propensity score matching, 1016/2032 (50.0%) were in the LAAO group and 1016/2032 (50.0%) in the LAAO plus ablation group. The mean ± SD age was 68.8 ± 9.3 years, with 815 (40.1%) participants being female. The mean ± SD CHA2DS2-VASc and HAS-BLED scores at baseline were 3.9 ± 1.8 and 2.4 ± 1.1, respectively. At three-year, compared to LAAO only, LAAO plus ablation was associated with a lower risk of cardiovascular death, stroke, systemic embolism (6.9%vs.10.4%, HRPSM:0.66, 95%CI: 0.49–0.89, P = 0.007), which was driven mainly by the lower risk of cardiovascular death (3.7% vs. 7.3%, HRPSM: 0.50, 95%CI: 0.34–0.74, P = 0.001). No significant between-group differences were noted for BARC-defined bleeding. LAAO plus ablation was associated with a lower risk of a composite of cardiovascular death, stroke, and systemic embolism than LAAO only at 3-year. However, given the observational nature of the current study, the results should be considered as hypothesis-generating only.Keywords
Funding Information
- Boston Scientific Corporation
This publication has 42 references indexed in Scilit:
- 5-Year Outcomes After Left Atrial Appendage ClosureJACC, 2017
- Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysisEuropean Journal of Preventive Cardiology, 2017
- Pearl and pitfall of catheter ablation for atrial fibrillation: Lesson from an extremely long-term 12-year outcome studyHeart Rhythm, 2017
- Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysisBMJ, 2016
- Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studiesEP Europace, 2016
- Concomitant cryoballoon ablation and percutaneous closure of left atrial appendage in patients with atrial fibrillationEP Europace, 2016
- Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillationEP Europace, 2015
- Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study)European Heart Journal, 2013
- Ablation for Atrial Fibrillation in Combination With Left Atrial Appendage Closure: First Results of a Feasibility StudyJournal of the American Heart Association, 2012
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011